Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Notes Payables (2016 - 2025)

Vycor Medical has reported Notes Payables over the past 16 years, most recently at $326978.0 for Q4 2025.

  • Quarterly Notes Payables rose 0.86% to $326978.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $326978.0 through Dec 2025, up 0.86% year-over-year, with the annual reading at $326978.0 for FY2025, 0.86% up from the prior year.
  • Notes Payables was $326978.0 for Q4 2025 at Vycor Medical, down from $340939.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $400873.0 in Q2 2022 and troughed at $303074.0 in Q2 2025.
  • The 5-year median for Notes Payables is $320873.0 (2021), against an average of $324722.4.
  • Year-over-year, Notes Payables grew 24.93% in 2022 and then dropped 24.31% in 2023.
  • A 5-year view of Notes Payables shows it stood at $320873.0 in 2021, then grew by 1.2% to $324711.0 in 2022, then rose by 1.1% to $328267.0 in 2023, then dropped by 1.24% to $324185.0 in 2024, then rose by 0.86% to $326978.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Notes Payables are $326978.0 (Q4 2025), $340939.0 (Q3 2025), and $303074.0 (Q2 2025).